Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
See Latest ArticlesClinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK
European Journal of Cancer Care, 09/08/09
Brearley S et al. – The deferral and dose reduction data indicate that cycles 1 and 2 are important and require careful management and clinical interventions in order to prevent high–grade adverse events.
Related Articles
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapy
Supportive Care in Cancer, 11/10/09
Relevance Score: 67%
Impact of radiation and chemotherapy on risk of dental abnormalities
Cancer, 10/20/09
Relevance Score: 67%
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The Sparc trial
Journal of Clinical Oncology, 10/08/09
Relevance Score: 67%
Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy
Journal of Clinical Oncology, 10/08/09
Relevance Score: 67%
Clinical compliance with an oral uracil/tegafur (UFT) plus leucovorin (LV) regimen as adjuvant chemotherapy in Japanese colorectal cancer patients
International Journal of Clinical Oncology, 11/02/09
Relevance Score: 66%
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
c-Jun activation is required for 4-hydroxytamoxifen-induced cell death in breast cancer cells
Oncogene, 11/25/09
Adenosine A1 receptor, a target and regulator of estrogen receptor action, mediates the proliferative effects of estradiol in breast cancer
Oncogene, 11/25/09
Extrapulmonary small cell carcinoma in breast and prostate
Clinical and Translational Oncology, 11/25/09
Today in Colorectal Cancer/Polyps...keeping you current
Receive free subspecialty "5-minute updates" via email
Knockdown of peroxisome proliferator-activated receptor-beta induces less differentiation and enhances cell–fibronectin adhesion of colon cancer cells
Oncogene, 11/25/09
A blood-based biomarker panel for stratifying current risk for colorectal cancer
International Journal of Cancer, 11/25/09
iNOS activity is necessary for the cytotoxic and immunogenic effects of doxorubicin in human colon cancer cells
Molecular Cancer, 11/24/09
Today in Pharmacology/Therapy...keeping you current
Receive free subspecialty "5-minute updates" via email
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
Oncogene, 11/25/09
Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
Investigational New Drugs, 11/25/09
Adding more content to screening: reactivation of FOXO as a therapeutic strategy
Clinical and Translational Oncology, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor